Company intelligence / Profile preview
IMAC Holdings
Franklin, Tennessee, United Statesimacregeneration.gcs-web.com ↗
- Ownership
- Public · BACK
- Employees
- ~15
- Development stage
- Commercial
01
Overview
IMAC Holdings completed a Phase 1 clinical trial of umbilical cord-derived allogenic mesenchymal stem cells for bradykinesia in Parkinson’s disease. The company also launched Ignite Proteomics LLC, offering a multi-protein test initially focused on advanced breast cancer to guide targeted treatment selection. Their LDTs are used by oncologists across the US.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Stem cell therapyLab developed tests (LDTs)Proteomic product and precision medicine services
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Not explicitly stated; licenses and patents support their clinical offerings.
04
Financials
- Market cap
- $378
- Total revenue
- $72.1K
- Enterprise value
- $3.8M
Beyond the preview
Go deeper on IMAC Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMAC Holdings.